After submitting the application for expansion of Xospata's benefits, the Health Insurance Review and Assessment Service's Cancer Disease Review Committee succeeded in setting the reimbursement standard. As a result, attention is focused on future procedures such as the schedule for submission to the Pharmaceutical Reimbursement Evaluation Committee. As Xospata is a PE drug, in the case of insurance coverage expansion, it is necessary to go through the drug price negotiation process with the Health Insurance Corporation. Xospata has been approved as monotherapy for patients with FLT3 mutation-positive relapse or Acute Myeloid Leukemia, but the current reimbursement standard allows up to four cycles only for patients